Flector tissugel used to treat capsular contracture after breast augmentation surgery.
Capsular contracture constitutes the main postoperative complication after breast augmentation by implant placement. To date, no systemic treatment known allows for improvement that does not simultaneously put the patient at risk for secondary complications of a more general nature. Flector Tissugel is the sole locally active antiinflammatory patch. Its durable local antiinflammatory effect is associated only with a risk for rare and highly limited side effects. After approximately 3 weeks of treatment, a high frequency of change from capsular contracture Baker 2 or 3 to Baker 1 occurs, provided the application was started no later than 3 months after the onset of capsular contracture.
Le Louarn
Claude
C
Department of Plastic Surgery, 59 rue Spontini, 75116 Paris, France. Lelouarn-claude@noos.fr
Buis
J
J
Auclair
E
E
D000287:Administration, Topical; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001940:Breast; D018427:Breast Implants; D002114:Calcinosis / Q000188:drug therapy* / Q000473:pathology; D003286:Contracture / Q000188:drug therapy*; D004008:Diclofenac / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005782:Gels; D006801:Humans; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005782:Gels; C064142:diclofenac hydroxyethylpyrrolidine; D004008:Diclofenac